The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The private equity firms expect to close the deal in the first half of 2026 with a valuation of up to $79 per share.

The investment firm noted that lower sequencing costs coupled with artificial intelligence are poised to catalyze diagnostics and precision medicine adoption.

NEW YORK – Becton Dickinson announced Wednesday that its new human papillomavirus self-collection solution has received certification under Europe's In Vitro Diagnostic Regulation. The new technology ...

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.

The firm's diagnostics revenues rose 4 percent to $2.46 billion, partially due to the growth of respiratory disease testing-related revenues from Cepheid.

NEW YORK – Having recently closed a pre-seed funding round, cancer diagnostics firm Procyon is targeting early 2026 for the UK launch of its urine-based test for early detection of pancreatic cancer.